L-N-苄基丝氨酸甲酯 | 123639-56-5

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 丝氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: L-N-苄基丝氨酸甲酯
• 中文别名: N-(苯基甲基)-l-丝氨酸甲酯
• 英文名称: (S)-N-benzylserine methyl ester
• 英文别名: methyl N-benzyl L-serinoate；N-benzylserine methyl ester；(S)-methyl 2-(benzylamino)-3-hydroxypropanoate；methyl benzyl-L-serinate；N-Benzyl-L-serine, methyl ester；methyl (2S)-2-(benzylamino)-3-hydroxypropanoate
• CAS: 123639-56-5
• 化学式: C₁₁H₁₅NO₃
• 分子量: 209.245
• InChiKey: GMZGWPPEZCREPP-JTQLQIEISA-N

物化性质

• 沸点：
  351.1±32.0 °C(Predicted)
• 密度：
  1.149±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于丙酮、氯仿、乙醇、乙酸乙酯、甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2922509090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  | 冰箱 |

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N-Benzyl-l-serine, methyl ester
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: N-Benzyl-l-serine, methyl ester
CAS number: 123639-56-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H15NO3
Molecular weight: 209.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  L-N-苄基丝氨酸甲酯 在 4-二甲氨基吡啶 、 lithium aluminium tetrahydride 、 偶氮二异丁腈 、 oxonium 、 四丁基氟化铵 、 三正丁基氢锡 、 对甲苯磺酸 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 甲苯 为溶剂， 反应 4.0h， 生成 (2R,3S)-1-benzyl-2-(hydroxymethyl)pyrrolidin-3-ol
  参考文献：
  名称：

  以L-丝氨酸为手性离析物的串联Michael-Henry反应对映体合成2-羟甲基-3-羟基-4-硝基-吡咯烷

  摘要：

  通过使用L-丝氨酸，通过串联Michael-Henry方法有效地制备了所有反式2-羟基甲基-3-羟基-4-硝基-吡咯烷的两种对映体。通过将其中之一转化为反式2-羟甲基-3-羟基吡咯烷，可以确定其立体化学，反式2-羟甲基-3-羟基吡咯烷是一种最近从Cast香精中分离出的天然化合物。

  DOI：

  10.1016/0040-4039(96)01671-1
• 作为产物：
  描述：

  苯甲醛 在 sodium tetrahydroborate 、 magnesium sulfate 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 28.0h， 生成 L-N-苄基丝氨酸甲酯
  参考文献：
  名称：

  A hypervalent iodine-mediated spirocyclization of 2-(4-hydroxybenzamido)acrylates – unexpected formation of δ-spirolactones

  摘要：

  在(S)-芳香酸的新总合成过程中，发现了一种新型的芳基-λ3-碘酸盐介导的氧化螺环化反应，适用于对位取代的酚衍生物。我们从易于获取的2-(4-羟基苯酰氨基)丙烯酸酯出发，成功构建了高达52%产率的螺环内酰胺。在不同的反应条件下，同样的前体经历了意想不到的氧化螺环化反应，生成了一种新型的δ-螺内酯，产率高达70%。

  DOI：

  10.1039/c2ob26815a

文献信息

• Structure-Based Design and Pharmacokinetic Optimization of Covalent Allosteric Inhibitors of the Mutant GTPase KRAS^G12C
  作者：Jason G. Kettle、Sharan K. Bagal、Sue Bickerton、Michael S. Bodnarchuk、Jason Breed、Rodrigo J. Carbajo、Doyle J. Cassar、Atanu Chakraborty、Sabina Cosulich、Iain Cumming、Michael Davies、Andrew Eatherton、Laura Evans、Lyman Feron、Shaun Fillery、Emma S. Gleave、Frederick W. Goldberg、Stephanie Harlfinger、Lyndsey Hanson、Martin Howard、Rachel Howells、Anne Jackson、Paul Kemmitt、Jennifer K. Kingston、Scott Lamont、Hilary J. Lewis、Songlei Li、Libin Liu、Derek Ogg、Christopher Phillips、Radek Polanski、Graeme Robb、David Robinson、Sarah Ross、James M. Smith、Michael Tonge、Rebecca Whiteley、Junsheng Yang、Longfei Zhang、Xiliang Zhao

  DOI：10.1021/acs.jmedchem.9b01720

  日期：2020.5.14

  efforts across industry and academia. The KRASG12C mutant represents an "Achilles heel" and has recently yielded to covalent targeting with small molecules that bind the mutant cysteine and create an allosteric pocket on GDP-bound RAS, locking it in an inactive state. A weak inhibitor at this site was optimized through conformational locking of a piperazine-quinazoline motif and linker modification

  尽管工业界和学术界做出了许多努力，但直接为重要的癌基因KRAS服药的尝试取得了有限的成功。KRASG12C突变体代表“致命弱点”，最近已与小分子共价靶向，这些小分子与突变体半胱氨酸结合并在GDP结合的RAS上形成一个变构口袋，从而将其锁定在非活性状态。通过哌嗪-喹唑啉基序的构象锁定和接头修饰优化了该位点的弱抑制剂。随后在哌嗪中引入关键甲基会导致效力，通透性，清除率和反应性增强，从而鉴定出具有高选择性，出色的跨物种药代动力学参数和体内功效的有效KRASG12C抑制剂。
• [EN] GUANIDINO-SUBSTITUTED QUINAZOLINONE COMPOUNDS AS MC4-R AGONISTS<br/>[FR] COMPOSES DE QUINAZOLINE SUBSTITUES PAR GUANIDINO CONSTITUANT DES AGONISTES DE MC4-R
  申请人：CHIRON CORP

  公开号：WO2004112793A1

  公开（公告）日：2004-12-29

  A variety of small molecule, guanidine-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases when administered to subjects. The compounds have the structure IA, IB, and IC where the values of the variables are defined herein.

  提供了一系列含有胍基的小分子化合物，能够作为MC4-R激动剂。当这些化合物被给予受试者时，它们对治疗MC4-R介导的疾病是有用的。这些化合物具有结构IA、IB和IC，其中变量的值在此定义。
• BTK INHIBITORS
  申请人：KIM RONALD M.

  公开号：US20140206681A1

  公开（公告）日：2014-07-24

  The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.

  本发明提供了根据式I提供的Bruton's酪氨酸激酶（Btk）抑制剂化合物，或其药学上可接受的盐，或包含这些化合物的药物组合物，并且用于治疗的使用。具体地，本发明涉及在治疗Btk介导的疾病中使用Btk抑制剂化合物。
• [EN] BTK INHIBITORS<br/>[FR] INHIBITEURS DE BTK
  申请人：MERCK SHARP & DOHME

  公开号：WO2014114185A1

  公开（公告）日：2014-07-31

  The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.

  本发明提供了根据式I或其药学上可接受的盐制备的Bruton's酪氨酸激酶（Btk）抑制剂化合物，或包含这些化合物的药物组合物，并且提供了这些化合物在治疗中的应用。具体而言，本发明涉及在治疗Btk介导的疾病中使用Btk抑制剂化合物。
• Hydrogen‐Borrowing Alkylation of 1,2‐Amino Alcohols in the Synthesis of Enantioenriched γ‐Aminobutyric Acids
  作者：Christopher J. J. Hall、William R. F. Goundry、Timothy J. Donohoe

  DOI：10.1002/anie.202100922

  日期：2021.3.22

  For the first time we have been able to employ enantiopure 1,2‐amino alcohols derived from abundant amino acids in C−C bond‐forming hydrogen‐borrowing alkylation reactions. These reactions are facilitated by the use of the aryl ketone Ph*COMe. Racemisation of the amine stereocentre during alkylation can be prevented by the use of sub‐stoichiometric base and protection of the nitrogen with a sterically

  我们首次能够在 C-C 键形成借氢烷基化反应中使用源自丰富氨基酸的对映体纯 1,2-氨基醇。使用芳基酮 Ph*COMe 可以促进这些反应。通过使用亚化学计量的碱并用位阻三苯甲烷（三苯甲基）或苄基保护氮，可以防止烷基化过程中胺立构中心的外消旋化。 Ph* 和三苯甲基在一锅中即可轻松裂解，得到 γ-氨基丁酸 (GABA) 盐酸盐产品，无需进一步纯化。这两个步骤可以依次进行，无需分离借氢中间体，从而无需柱色谱法。